Loading organizations...
Yijing Capital is an investment firm providing equity investment services for both proprietary and third-party funds. Its core strategy focuses on high-growth potential industries, particularly advanced technology and life sciences. The firm leverages an experienced team to identify and support promising enterprises within these critical sectors.
Founded in 2015, Yijing Capital was established with a strategic vision to drive innovation within its chosen investment domains. Its inception reflects a commitment to applying extensive industry knowledge and investment expertise from its core team to build a robust portfolio in dynamic markets.
The firm serves investors seeking specialized sector exposure and portfolio companies needing capital and strategic guidance. Yijing Capital's mission is to help entrepreneurs realize their full strategic and commercial potential, actively participating in human progress. Its long-term vision centers on fostering innovation and sustainable growth across its global investment activities.
Key people at Yijing Capital.
Yijing Capital was founded in 2015 by Jianqun Zhang (Chairman & Founder).
Yijing Capital has 6 tracked investments across 6 companies. The latest tracked deal is $52.0M Series A in Arnatar Therapeutics in August 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Aug 25, 2025 | Arnatar Therapeutics | $52.0M Series A | 3E Bioventures Capital, Eight Roads Ventures | Chuanhua Capital, F Prime Capital, Gaorong Capital, Hongsheng Capital, NEW Alliance Capital |
| Apr 29, 2024 | Phomera | $13.8M Series A | Yijing Capital | BASF Venture Capital, Longchenjia |
| May 19, 2023 | Taichu Biotechnology | $56.9M Series A | IDG Capital | Shanghai Healthcare Capital |
| Nov 13, 2020 | Zhiketong Technology | $50.0M Series D | — | Qiyuan Investment, Sequoia Capital, Shunwei Capital |
| Jun 16, 2020 | etherna immunotherapies | $38.4M Series B | — | BNP Paribas Fortis Private Equity, Boehringer Ingelheim, Fund+, Grand Decade, LSP, Novalis LifeSciences, Omega Funds, PMV |
| Jun 16, 2020 | Etherna | $38.4M Series B | — | BNP Paribas Fortis Private Equity, Boehringer Ingelheim Venture Fund, Fund+, Grand Decade, LSP, Novalis LifeSciences, Omega Funds, PMV |
Key people at Yijing Capital.
